Latest Recruitment News

UNITH Ltd reports a 9.3% rise in Q3 FY25 cash receipts driven by its B2C subscription surge and a landmark pharmaceutical contract, alongside strategic platform upgrades and leadership changes.

Invion Limited has progressed its Photosoft clinical programs with new patient dosing and an expanded collaboration with Hanlim Pharm, backed by a successful $2 million share placement to accelerate development.

Group 6 Metals reported steady production at its Dolphin Tungsten Mine in Q1 2025, alongside significant progress in its recapitalisation plan and a strengthened financial position amid a tightening global tungsten market.

St George Mining has completed its acquisition of the Araxá niobium-rare earth project in Brazil, announcing a maiden JORC-compliant resource and securing a strategic EPC+F partnership to fast-track development.

Dimerix Limited advances its Phase 3 kidney disease trial with FDA acceptance of proteinuria as a primary endpoint and clinches a lucrative licensing agreement in Japan worth up to AU$107 million plus royalties.

TrivarX has launched a pivotal mental health clinical trial in partnership with the US Department of Veterans Affairs, leveraging its innovative ECG-based technology to screen for major depressive episodes. The company also secured $2.25 million in funding, positioning it for regulatory milestones ahead.

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

RLF AgTech has secured major national distribution agreements in Australia, launched a comprehensive retail rollout, and restructured its manufacturing arm, LiquaForce, to drive growth and operational efficiency. The company also reported strong financial performance and expanded its footprint across Asia.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

Syntara Limited reports significant clinical progress with its lead myelofibrosis drug SNT-5505 and launches a new trial for its next-generation anti-fibrotic skin treatment, supported by a solid $18 million cash reserve.